$14.77
▲ +0.2% Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings
Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT)
Overview
52-week range
$14
$31
5% of range
Avg surprise (last 2)
-325.0%
Avg reaction (last 1)
+2.3%
100% positive
Latest IV / EM
255%
EM ±15.0% · $15 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.24 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.31 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.76 | $-0.10 | -660.0% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-0.09 | $-0.10 | +10.0% | — | +2.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.08 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.09 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.03 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.02 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 23, 2026 | Jun/2026 | AMC | -$0.26 | -$0.76 | +65.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | $-58M | $-60M |
| Net income | $-189M | — | $-232M | $-566M | $-63M | — | $-56M | $-60M |
| EPS (diluted) | $-0.24 | — | $-0.31 | $-0.76 | $-0.09 | — | $-0.08 | $-0.09 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $107M | $225M | $239M | $298M | $212M | $105M | $94M | $28M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $617M | $720M | $246M | $309M | $371M | $424M | $490M | $329M |
| Total assets | $648M | $751M | $262M | $324M | $384M | $436M | $503M | $342M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $102M | $92M | $69M | $65M | $39M | $47M | $65M | $147M |
| Total equity | $546M | $659M | $192M | $259M | $344M | $389M | $438M | $195M |